Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 89,500 shares, a growth of 41.2% from the January 31st total of 63,400 shares. Based on an average trading volume of 223,600 shares, the short-interest ratio is presently 0.4 days. Currently, 17.1% of the company’s stock are sold short.

Revelation Biosciences Trading Down 3.3 %

Shares of REVB stock traded down $0.12 during trading hours on Tuesday, reaching $3.38. 20,004 shares of the company’s stock were exchanged, compared to its average volume of 102,696. Revelation Biosciences has a fifty-two week low of $3.19 and a fifty-two week high of $60.80. The stock’s 50 day moving average is $5.58 and its 200-day moving average is $10.40. The company has a market cap of $904,500.00, a price-to-earnings ratio of -0.01 and a beta of 0.19.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.